Senti Biosciences Holdings, Inc. (SNTI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600K 1.2M 1.8M Q1 '21: 44K Q2 '21: 778K Q3 '21: 926K Q4 '21: 543K Q1 '22: 854K Q2 '22: 1.1M Q3 '22: 1.5M Q4 '22: 59K Q1 '23: 1M Q2 '23: 687K Q3 '23: 255K Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q1 '26: 16K Q2 '26: 17K Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '21: -9.1M Q2 '21: -9M Q3 '21: -11.4M Q4 '21: -10.9M Q1 '22: -11.8M Q2 '22: -21.8M Q3 '22: -14.7M Q4 '22: -16.8M Q1 '23: -15M Q2 '23: -15.2M Q3 '23: -43.9M Q4 '23: -18.7M Q1 '24: -16.3M Q2 '24: -13.4M Q3 '24: -15.2M Q4 '24: -16.2M Q1 '25: -16.4M Q2 '25: -16.8M Q3 '25: -16.9M Q4 '25: -18.6M Q1 '26: -4.6M Q2 '26: -14.5M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '21: -21M Q2 '21: -12M Q3 '21: -11.4M Q4 '21: -3.4M Q1 '22: -11.8M Q2 '22: -11.6M Q3 '22: -16.6M Q4 '22: -58.2M Q1 '23: -18.7M Q2 '23: -18.7M Q3 '23: -14.9M Q4 '23: -71.1M Q1 '24: -12.1M Q2 '24: -11.2M Q3 '24: -28.9M Q4 '24: -610K Q1 '25: -14.1M Q2 '25: -14.7M Q3 '25: -18.1M Q4 '25: -14.5M Q1 '26: -4.2M Q2 '26: -12.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q1 '21: -12.9M Q2 '21: -934.7K Q3 '21: -8.8M Q4 '21: -12M Q1 '22: -10.1M Q2 '22: -5.7M Q3 '22: -10.1M Q4 '22: -9M Q1 '23: -16.3M Q2 '23: -13.7M Q3 '23: -15.4M Q4 '23: -7M Q1 '24: -11.7M Q2 '24: -8.3M Q3 '24: -7.9M Q4 '24: -13.5M Q1 '25: -14.1M Q2 '25: -13.1M Q3 '25: -9.4M Q4 '25: -6.9M Q1 '26: -7.5M Q2 '26: -14.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -9.7M Q4 '21: -16M Q1 '22: -17.4M Q2 '22: -17M Q3 '22: -24.3M Q4 '22: -17.5M Q1 '23: -22.8M Q2 '23: -17.3M Q3 '23: -17.2M Q4 '23: -7M Q1 '24: -11.7M Q2 '24: -8.3M Q3 '24: -7.9M Q4 '24: -13.5M Q1 '25: -14.1M Q2 '25: -13.3M Q3 '25: -9.4M Q4 '25: -6.9M Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '21: 2.9M Q3 '21: 2.9M Q1 '22: 3.2M Q2 '22: 13.4M Q3 '22: 43.4M Q1 '23: 44.1M Q2 '23: 4.4M Q3 '23: 4.4M Q1 '24: 4.6M Q2 '24: 4.6M Q3 '24: 4.6M Q1 '25: 10M Q2 '25: 26.1M Q3 '25: 26.2M Q1 '26: 31M Q2 '26: 31.1M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q4 '21: -19.00 Q1 '22: -15.42 Q2 '22: -12.15 Q3 '22: -8.63 Q4 '22: -2.23 Q1 '23: 1.07 Q2 '23: -2.29 Q3 '23: -5.27 Q4 '23: -12.19 Q1 '24: -14.42 Q2 '24: -12.65 Q3 '24: -15.60 Q4 '24: -12.03 Q1 '25: -10.79 Q2 '25: -8.90 Q3 '25: -3.28 Q4 '25: -3.14 Q1 '26: -1.87 Q2 '26: -1.72 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.